Compound brief
Evidence brief. Not treatment advice or a safety clearance. Last evidence update: September 2026.
This fragment omits the rest of growth hormone, including the parts that drive IGF-1 through the GH receptor. It should not be modeled as full GH.
Forum "fat-loss GH" talk collapses this fragment into somatropin. The sequences are not the same.
The C-terminal piece of growth hormone has been studied for lipolysis without the full receptor biology of somatropin. Fatty-acid oxidation is the marker used here.
Because the GH-receptor binding surface of intact GH is missing, IGF-1 should not be assumed to rise the way it does with tesamorelin or somatropin.
Forum themes are unverified. They do not outrank a study, and they are not a dose.
Fragment as diet drug · unverified
Fat-loss logs describe this GH fragment as growth hormone without growth-hormone effects. The missing GH-receptor surface is the chemistry those logs skip.
Theme summarized from public discussion. Not a quoted post, not a trial, and not a dose.